Add to ORKG7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCEWOS: 000413730202068…European Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple SclerosisMerckMerck & Company; NovartisNovartis; Bayer-ScheringBayer AG; TevaMurat Terzi received travel grants from Merck, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis
The article discusses the prospects for the use of the new drug teriflunomide for the treatment of p...
Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing-...
BACKGROUND: Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sc...
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Com...
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) /...
Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the ...
Introduction: We have different treatment alternatives for relapsing-remitting multiple sclerosis–RR...
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
AbstractPurposeThe purpose was to summarize US prescribing information for teriflunomide in the trea...
Background: The aim of the study was to evaluate the achievement of ‘no evidence of disease activity...
Background: The aim of the study was to evaluate the achievement of ‘no evidence of disease activity...
Objective: To identify baseline factors associated with disease activity in patients with relapsing–...
Background: Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of ...
Relapsing-remitting multiple sclerosis (RRMS) is a degenerative, inflammatory disease of the central...
BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple scl...
The article discusses the prospects for the use of the new drug teriflunomide for the treatment of p...
Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing-...
BACKGROUND: Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sc...
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Com...
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) /...
Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the ...
Introduction: We have different treatment alternatives for relapsing-remitting multiple sclerosis–RR...
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
AbstractPurposeThe purpose was to summarize US prescribing information for teriflunomide in the trea...
Background: The aim of the study was to evaluate the achievement of ‘no evidence of disease activity...
Background: The aim of the study was to evaluate the achievement of ‘no evidence of disease activity...
Objective: To identify baseline factors associated with disease activity in patients with relapsing–...
Background: Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of ...
Relapsing-remitting multiple sclerosis (RRMS) is a degenerative, inflammatory disease of the central...
BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple scl...
The article discusses the prospects for the use of the new drug teriflunomide for the treatment of p...
Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing-...
BACKGROUND: Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sc...